Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva Pharmaceutical Industries has launched a liquid formulation of Treanda (bendamustine HCI) Injection in the US indicated to treat patients with chronic lymphocytic leukemia (CLL).
Subscribe to our email newsletter
The new liquid formulation eliminates the need of reconstituting lyophilized powder with sterile water before adding the required dose of medicine to the infusion bag and administering to a patient.
By reducing the need for reconstitution, preparation time for healthcare professionals is reduced.
Teva Oncology vice-president and general manager Paul Rittman said: "Treanda continues to play a valuable role in the treatment of patients with CLL or indolent B-cell NHL that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
"With the new liquid formulation of Treanda, we are not only building on the legacy of this important product, but also furthering Teva’s commitment to continuously improving our medicines."
The drug is indicated to treat patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
The chemical structure of the drug is synthesized to combine an alkylating group and a purine-like benzimidazole component.